How does atorvastatin lower LDL cholesterol?
Atorvastatin lowers LDL by blocking an early step in cholesterol production in the liver. It is a statin that inhibits HMG‑CoA reductase, the key enzyme that converts HMG‑CoA into mevalonate, which the liver needs to make cholesterol. When liver cholesterol synthesis drops, liver cells increase uptake of cholesterol from the blood by upregulating LDL receptors. As a result, more LDL particles are removed from circulation and measured LDL cholesterol falls.
Why does blocking cholesterol production increase LDL receptor activity?
With less newly made cholesterol available inside hepatocytes (liver cells), the cell senses a cholesterol deficit. That drives increased expression of LDL receptors on the hepatocyte surface. More LDL receptors means the liver pulls more LDL particles out of the bloodstream, lowering plasma LDL levels.
What happens downstream of LDL lowering?
By reducing LDL cholesterol, atorvastatin also tends to lower risk of atherosclerotic cardiovascular events over time. The clinical effect comes from improving the cholesterol balance that drives plaque formation and progression, even though the immediate pharmacologic action is the enzyme inhibition and subsequent LDL receptor upregulation.
Are there LDL-lowering mechanisms besides LDL receptor upregulation?
The dominant mechanism is HMG‑CoA reductase inhibition leading to increased LDL receptor expression. Statins can also reduce overall hepatic cholesterol synthesis and influence circulating lipoprotein metabolism, but the LDL receptor pathway is the central explanation for how atorvastatin specifically lowers LDL cholesterol.
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com tracks patent and exclusivity information for drugs, which can help if you are researching atorvastatin’s legal status rather than its biology. It does not provide the clinical mechanism of action itself.